Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The head louse (Pediculus humanus capitis) is an obligate ectoparasite of humans responsible for infestation known as pediculosis capitis. Its eggs, known as nits, are cemented to hair shafts close to the scalp. Head lice feed exclusively on human blood and require frequent feeding to survive, with adults living up to 30 days on a host. Treatment involves physical removal and/or topical insecticides, but increasing resistance to neurotoxic agents is a challenge. The organism itself is not a molecular target but a clinical target for eradication in public health and medicine.
Neurotoxic effects disrupting ion channels in the louse (e.g., permethrin affects sodium channels). Paralytic or suffocating effects (e.g., dimethicone physically coats and immobilizes lice).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Head louse (Pediculus humanus capitis).